Vienna, Austria – Construction work on Biomay’s new headquarters and biotech manufacturing facility in Aspern Seestadt, Vienna, is progressing on schedule. Seven months after the groundbreaking ceremony in September 2020, the constructing shell has now been accomplished. Ongoing actions are at the moment targeted on the inside works and the set up of the advanced warmth, air flow and air con (HVAC) and utility methods.
Construction Project of Biomay’s Manufacturing Facility Fully on Schedule
Dr. Hans Huber, Chief Executive Officer of Biomay stated: “We are delighted and impressed to witness the rapid and timely progress of our building project. Internal and external engineering teams and the construction workers are doing an excellent job. It is a pleasure to see how all the team members are working together effectively in a concerted effort to meet Biomay’s goals in terms of schedule, quality and budget. Seeing the satisfying progress, we are highly confident that the remaining half of the project will stay on track as well.”
As for the months to come back, the constructing as such is deliberate to be accomplished in September 2021, adopted by the manufacturing gear and course of utilities to be put in by Q3/2021. Biomay and its workers will transfer to the brand new website on the finish of this 12 months. After commissioning and qualification, the corporate will begin up manufacturing operations for its shoppers in Q1/2022.
About the Facility
Quite a lot of parallel GMP manufacturing strains might be erected on a complete flooring space of about 4000 sq. meters, growing Biomay’s capacities by an element of 10 with respect to batch measurement and quantity (gross bioreactor scales: 5L, 50L, 150L and 750L). Furthermore, a devoted space of the constructing will permit the manufacturing of modern, personalised (patient-specific) batches.
Biomay AG is a biopharmaceutical contract improvement and manufacturing group (CDMO) with worldwide attain. In explicit, Biomay is acknowledged as provider for plasmid DNA (pDNA), recombinant proteins and messenger RNA (mRNA). Biomay’s shoppers embrace start-ups, midsize biotech firms and multinational enterprises, predominantly from Europe and the US. Beside manufacturing of energetic substances and drug merchandise based on GMP requirements, the corporate gives course of and assay improvement in addition to manufacturing of microbial cell banks.
Dr. Christian Gruber / firstname.lastname@example.org / +43-7966296-100 / www.biomay.com